CDDD11-8

CDDD11-8 is an orally active, potent and selective inhibitor of CDK9 and FLT3-ITD, with Ki values of 8 and 13 nM, respectively. CDDD11-8 reduces the proliferation of leukemia cell lines and was particularly effective against those harboring FLT3-ITD mutation[1][2].

Product Specifications

CAS Number

[2241659-94-7]

UNSPSC

12352005

Target

CDK; FLT3

Type

Reference compound

Related Pathways

Cell Cycle/DNA Damage; Protein Tyrosine Kinase/RTK

Applications

Cancer-Kinase/protease

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/cddd11-8.html

Purity

99.62

Solubility

10 mM in DMSO

Smiles

CC1=CN=C(N[C@@H]2CC[C@@H](N)CC2)N=C1C3=CN=C(C=C4)N3C=C4C5=CC=CC=C5

Molecular Formula

C24H26N6

Molecular Weight

398.50

References & Citations

[1]Anshabo AT, et al. An Orally Bioavailable and Highly Efficacious Inhibitor of CDK9/FLT3 for the Treatment of Acute Myeloid Leukemia. Cancers (Basel) . 2022 Feb 22;14 (5) :1113.|[2]Mustafa EH, et al. Selective inhibition of CDK9 in triple negative breast cancer. Oncogene. 2023 Nov 24.